The Affiliated Hospital Of Xuzhou Medical University

This early study is testing a new drug, HN2302 (a type of in vivo CAR-T therapy), in just 6 people with refractory myasthenia gravis — a condition where standard treatments fail. The main goal is to see if the drug is safe and tolerable. Researchers will also check if it helps wi…

This early-phase trial tests whether combining an experimental drug (AT1019), targeted radiation (SBRT), and an immunotherapy (PD-1 inhibitor) is safe for people with advanced solid tumors. About 12 participants will receive the combination and be monitored for side effects and t…

This phase 2 trial is testing a combination of five drugs—tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone—in 40 people newly diagnosed with angioimmunoblastic T-cell lymphoma (AITL), a rare and aggressive blood cancer. The goal is to see if this …

This study looks at how a person's genes influence their response to GLP-1 RA drugs (like exenatide and liraglutide) for type 2 diabetes. Researchers will analyze blood samples from 300 patients to find genetic markers that predict whether the drug lowers blood sugar and weight. …